About DPharm: Disruptive Innovations 2019

Nine years ago, a Pfizer executive coined the concept of DPharm: to truly challenge conventional methods of conducting clinical trials to address rising costs, protracted time to market, and a heavy patient and investigator burden. We are delighted to announce that Dr Scott Gottlieb, 23rd Commissioner of the FDA, has chosen DPharm to deliver an industry keynote with his views on modernizing clinical trials.

More than 20 pharma companies are reporting on specific innovations they have developed to better deliver new medicines. DPharm 2019 covers the full spectrum of clinical research, including virtual trials, digital applications, real-world data, big data management, AI applications, MAPs, EHR eSource operations, patient-centric strategies, new business models, collaborations and technologies.